155 related articles for article (PubMed ID: 31142278)
1. Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis.
He C; Zhang Y; Cai Z; Lin X
BMC Cancer; 2019 May; 19(1):509. PubMed ID: 31142278
[TBL] [Abstract][Full Text] [Related]
2. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database.
Hu H; Xu Y; Zhang Q; Gao Y; Wu Z
Expert Rev Anticancer Ther; 2024 Jun; 24(6):467-476. PubMed ID: 38656796
[TBL] [Abstract][Full Text] [Related]
3. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis.
Meng Z; Cao M; Zhang Y; Liu Z; Wu S; Wu H
BMC Gastroenterol; 2019 Apr; 19(1):59. PubMed ID: 31014264
[TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
[TBL] [Abstract][Full Text] [Related]
6. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
7. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
Zhang K; Dong S; Jing YH; Gao HF; Chen LY; Hua YQ; Chen H; Chen Z
BMC Cancer; 2020 Jun; 20(1):541. PubMed ID: 32517802
[TBL] [Abstract][Full Text] [Related]
8. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Shi J; Li X; Wu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of chemotherapy in different histological types of pancreatic cancer: a PSM-based study using the SEER database.
Luo C; Fan L; Lun W; Ma M; Liang L; Yu C
J Chemother; 2024 Apr; 36(2):167-178. PubMed ID: 38481380
[TBL] [Abstract][Full Text] [Related]
10. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Amin S; Mhango G; Lin J; Aronson A; Wisnivesky J; Boffetta P; Lucas AL
Am J Gastroenterol; 2016 Sep; 111(9):1350-7. PubMed ID: 27430290
[TBL] [Abstract][Full Text] [Related]
11. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8
Chen HY; Wang X; Zhang H; Liu XB; Tan CL
World J Gastroenterol; 2019 Dec; 25(46):6752-6766. PubMed ID: 31857777
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.
Chen K; Pan Y; Huang CJ; Chen QL; Zhang RC; Zhang MZ; Wang GY; Wang XF; Mou YP; Yan JF
BMC Cancer; 2021 Apr; 21(1):382. PubMed ID: 33836678
[TBL] [Abstract][Full Text] [Related]
14. Early-onset pancreatic cancer: a population-based study using the SEER registry.
Ansari D; Althini C; Ohlsson H; Andersson R
Langenbecks Arch Surg; 2019 Aug; 404(5):565-571. PubMed ID: 31377855
[TBL] [Abstract][Full Text] [Related]
15. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.
Kaiser J; Hinz U; Mayer P; Hank T; Niesen W; Hackert T; Gaida MM; Büchler MW; Strobel O
Eur J Surg Oncol; 2021 Jul; 47(7):1734-1741. PubMed ID: 33622577
[TBL] [Abstract][Full Text] [Related]
18. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
19. The impact of different metastatic patterns on survival in patients with pancreatic cancer.
He C; Huang X; Zhang Y; Lin X; Li S
Pancreatology; 2021 Apr; 21(3):556-563. PubMed ID: 33518454
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
